SCHEMBL4818918

SCHEMBL4818918

CCN(CC)Cc1ccc2c(c1)-c1[nH]nc(-c3ccsc3)c1C2

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.70
KIT P10721 9/20 0.70
FLT1 P17948 9/20 0.70
FLT4 P35916 2/20 0.70
TEK Q02763 2/20 0.70
LCK P06239 1/20 0.65
CYP3A4 P08684 1/20 0.65
FGFR1 P11362 1/20 0.65
FGFR2 P21802 1/20 0.65
FGFR4 P22455 1/20 0.65
FGFR3 P22607 1/20 0.65
CHEK1 O14757 8/20 0.49
IKBKB O14920 1/20 0.44
MAP4K4 O95819 1/20 0.44
PIM1 P11309 1/20 0.44
RPS6KB1 P23443 1/20 0.44
CDK2 P24941 1/20 0.44
MARK3 P27448 1/20 0.44
AKT1 P31749 1/20 0.44
AKT2 P31751 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4816318 0.85 KDR (0.89) KDRKITFLT1FLT4TEK
SCHEMBL4813702 0.81 KDR (0.89) KDRKITFLT1FLT4TEK
SCHEMBL4811743 0.81 KDR (0.76) KDRKITFLT1FLT4TEK
SCHEMBL4817076 0.80 KDR (0.72) KDRKITFLT1FLT4TEK
SCHEMBL4815092 0.80 KDR (0.88) KDRKITFLT1FLT4TEK
SCHEMBL4816399 0.79 KDR (0.64) KDRKITFLT1FLT4TEK
SCHEMBL4823887 0.79 KDR (0.70) KDRKITFLT1FLT4TEK
SCHEMBL4817151 0.79 KDR (1.00) KDRKITFLT1FLT4TEK
SCHEMBL4816496 0.79 KDR (0.70) KDRKITFLT1FLT4TEK
SCHEMBL4815241 0.78 KDR (0.89) KDRKITFLT1FLT4TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740579-B1 TRICYCLIC PYRAZOLE KINASE INHIBITORS ABBVIE INC (US) 2015-08-19 EP disclosed
US-7468371-B2 Tricyclic pyrazole kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-12-23 US disclosed
EP-1740579-A1 TRICYCLIC PYRAZOLE KINASE INHIBITORS Abbott Laboratories (US) 2007-01-10 EP disclosed
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors ABBVIE INC. 2006-01-19 US disclosed
WO-2005095387-A1 TRICYCLIC PYRAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors PRKDC, PRKACA, PIK3C3 KDR 666/4885KIT 472/4885FLT1 850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.